Synapse - Chau Dang

Results (273)

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Meeting Abstract

Tanioka, M.; Fan, C.; Carey, L. A.; Hyslop, T.; Pitcher, B. N.; Parker, J. A.; Hoadley, K. A.; Henry, N. L.; Tolaney, S.; Dang, C.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience

Journal Article

Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
The Oncologist (2017)

Fulltext@MSK | Save

Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel plus cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer

Meeting Abstract

Blum, J. L.; Flynn, P. J.; Yothers, G.; Asrnar, L.; Geyer, C. E.; Jacobs, S. A.; Robert, N. J.; Atkins, J. N.; O'Shaughnessy, J.; Dang, C. T.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Current standards and new treatment insights in HER2-driven metastatic breast disease

Journal Article

Wang, R.; Dang, C.
American Journal of Hematology/Oncology (2016)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution

Meeting Abstract

Argolo, D.; Friedman, M.; Smyth, L.; Iyengar, N.; Singh, J.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
Cancer Research (2016)

Fulltext@MSK | Save

Initial results of a prospective clinical trial of (18)F-fluciclovine PET/CT in newly diagnosed invasive ductal and invasive lobular breast cancers

Journal Article

Ulaner, G. A.; Goldman, D. A.; Gönen, M.; Pham, H.; Castillo, R.; Lyashchenko, S. K.; Lewis, J. S.; Dang, C.
Journal of Nuclear Medicine (2016)

Fulltext@MSK | Save

Exercise and prognosis on the basis of clinicopathologic and molecular features in early-stage breast cancer: The LACE and pathways studies

Journal Article

Jones, L. W.; Kwan, M. L.; Weltzien, E.; Chandarlapaty, S.; Sternfeld, B.; Sweeney, C.; Bernard, P. S.; Castillo, A.; Habel, L. A.; Kroenke, C. H.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study

Journal Article

Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
Breast Cancer Research and Treatment (2016)

Fulltext@MSK | Save